Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes that the FDA approval without a boxed warning is a significant positive for Bristol Myers shares.
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated schizophrenia drug, Cobenfy. It’s the first novel treatment for the debilitating mental disorder in over seven decades.
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure, the personal consumption expenditures ...
Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh ...
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target remains the same with $37.00. Terence Flynn ...
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback